Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Deferiprone (Primary) ; Deferasirox
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms DEEP-2
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
- 21 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.